528 research outputs found
Teede, W H, 16774
No full textThis record was harvested from a previous catalogue system and will be withdrawn in 2025. Information in this record may be superseded or incomplete. Visit this record in UMA's new catalogue at: https://archives.library.unimelb.edu.au/nodes/view/420818Surname: TEEDE. Given Name(s) or Initials: W H. Military Service Number or Last Known Location: 16774. Missing, Wounded and Prisoner of War Enquiry Card Index Number: 50089.245528
Item: [2016.0049.53079] "Teede, W H, 16774
Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society
No full textCopyright © 2009 American Society for Reproductive Medicine Published by Elsevier Inc.ObjectiveTo summarize current evidence on lifestyle management (dietary, exercise, or behavioral interventions) of obesity in women with polycystic ovary syndrome (PCOS), to indicate gaps in knowledge, and to review the medical and surgical alternatives for weight management.DesignExpert panel appointed by the Androgen Excess and PCOS Society (AEPCOS Society) to review the literature and draft the initial report after a consensus process via electronic communication. The initial report was reviewed and critiqued by all expert panel members and the AEPCOS Society Board of Directors and modified based on their comments.Conclusion(s)Lifestyle management should be used as the primary therapy in overweight and obese women with PCOS for the treatment of metabolic complications. For reproductive abnormalities, lifestyle modification may improve ovulatory function and pregnancy. Data are preliminary for improvement in pregnancy and live-birth rates, and further research is needed. There is currently no evidence that modifying dietary macronutrient composition offers additional benefits over conventional dietary approaches for weight loss, and further research is needed. Emerging evidence suggests that exercise offers additional benefits to dietary energy restriction for reproductive features of PCOS.Lisa J. Moran, Renato Pasquali, Helena J. Teede, Kathleen M. Hoeger and Robert J. Norma
Cardiometabolic risks in polycystic ovary syndrome: non-traditional risk factors and the impact of obesity
No full textAbstract not availableWei-Ling Chiu, Jacqueline Boyle, Amanda Vincent, Helena Teede, Lisa J. Mora
Polycystic ovary syndrome: what do the new guidelines recommend?
No full textPolycystic ovary syndrome (PCOS) is a prevalent, chronic, heterogeneous condition with reproductive, metabolic and psychological features. Treatment focuses on relieving symptoms and preventing future complications with a strong emphasis on lifestyle intervention, augmented with targeted medical therapy. New national evidence-based guidelines are now available to help clinicians assess and manage women with PCOS. © Dr Najeeb Layyous/Science Photo Library.Anju E Joham, Helena J Teede, Robert J Normanhttp://www.medicinetoday.com.au/2012/may/article/polycystic-ovary-syndrome-what-do-new-guidelines-recommend-0#.UurbIFP84X
Polycystic ovarian syndrome - Insights into the enigma that is PCOS today
No full textThe original publication can be found at www.springerlink.comPolycystic ovary syndrome (PCOS) is an endocrine condition with both reproductive and metabolic implications. It affects 6–10% of reproductive aged women making it the most common endocrinopathy in this group of women. It is a frequent cause of infertility, has potential for serious long-term complications, and represents a major cost burden on the health care system. Although PCOS is a heterogeneous condition and many research challenges remain, it is imperative that clinicians are aware of the recent advances in the area. This special section reviews the current literature on PCOS including controversies in diagnostic criteria, etiology, metabolic and cardiovascular implications, and the debate over ideal therapies focusing on lifestyle modification, insulin sensitisers, and infertility therapyH.J. Teede and R. Norma
Sex hormone binding globulin, but not testosterone, is associated with the metabolic syndrome in overweight and obese women with polycystic ovary syndrome
No full textAbstract not availableL.J. Moran, H.J. Teede, M. Noakes, P.M. Clifton, R.J. Norman and G.A. Witterthttp://www.jendocrinolinvest.it/jei/en/abstract.cfm?articolo_id=902
Vitamin D is independently associated with depression in overweight women with and without PCOS
No full textBackground: Depression, anxiety, and inflammation are common in polycystic ovary syndrome (PCOS). Inflammation may adversely impact on mood and vitamin D has been associated with both mood disorders and inflammation in the general population, but these relationships have not been studied in PCOS. The aim of this study was to investigate the association among 25 hydroxy-Vitamin D (25OHVD) status, anxiety, depression, and inflammation in women with and without PCOS. Methods: Cross-sectional study in overweight or obese premenopausal women with (n = 50) and without (n = 23) PCOS. Primary outcome measures were 25OHVD, mood (Hospital Anxiety and Depression questionnaire), and inflammation (highly sensitive C-reactive protein (hsCRP)). Results: Vitamin D deficiency (25OHVD<50 nmol/L) (46% versus 39%, p = 0.311) and 25OHVD (50.4 ± 22.2 nmol/L versus 51.6 ± 19.0 nmol/L, p = 0.828) were not significantly different in women with and without PCOS. For all women combined, 25OHVD was the only significant independent predictor of depression (β = −0.063 ± 0.021, p = 0.005) and hsCRP (β = −0.041 ± 0.015, p = 0.010). Conclusions: Vitamin D deficiency is common in both women with and without PCOS with no differences between the groups. Vitamin D is independently associated with depression and inflammation in overweight women both with and without PCOS. Further investigation to clarify the interrelationship among vitamin D, inflammation and depression is required to identify optimal prevention and treatment strategies for psychological and metabolic dysfunction in PCOS.L. J. Moran, H. J. Teede & A. J. Vincen
The association of the lipidomic profile with features of polycystic ovary syndrome
No full textPolycystic ovary syndrome (PCOS) affects up to 18% of reproductive-aged women with reproductive and metabolic complications. While lipidomics can identify associations between lipid species and metabolic diseases, no research has examined the association of lipid species with the pathophysiological features of PCOS. The aim of this study was to examine the lipidomic profile in women with and without PCOS. This study was a cross-sectional study in 156 age-matched pre-menopausal women (18-45 years, BMI >20 kg/m2; n = 92 with PCOS, n = 64 without PCOS). Outcomes included the association between the plasma lipidomic profile (325 lipid species (24 classes) using liquid chromatography mass spectrometry) and PCOS, adiposity, homeostasis assessment of insulin resistance (HOMA), sex hormone-binding globulin (SHBG) and free androgen index (FAI). There were no associations of the lipidomic profile with PCOS or testosterone. HOMA was positively associated with 2 classes (dihydroceramide and triacylglycerol), SHBG was inversely associated with 2 classes (diacylglycerol and triacylglycerol), FAI was positively associated with 8 classes (ceramide, phosphatidylcholine, lysophosphatidylcholine, phosphatidylethanolamine, lysophosphatidylethanolamine, phosphatidylinositol, diacylglycerol and triacylglycerol) and waist circumference was associated with 8 classes (4 positively (dihydroceramide, phosphatidylglycerol, diacylglycerol and triacylglycerol) and 4 inversely (trihexosylceramide, GM3 ganglioside, alkenylphosphatidylcholine and alkylphosphatidylethanolamine)). The lipidomic profile was primarily related to central adiposity and FAI in women with or without PCOS. This supports prior findings that adiposity is a key driver of dyslipidaemia in PCOS and highlights the need for weight management through lifestyle interventions.L J Moran, P A Mundra, H J Teede and P J Meikl
Symptoms, health behavior and understanding of menopause therapy in women with premature menopause
No full textOBJECTIVE: To explore symptoms, understanding of menopausal therapies, medication use and health-related behavior in women with and without premature menopause. METHODS: Cross-sectional, questionnaire-based study involving a community-based sample of 77 women in Australia: 23 premenopausal, 25 with premature ovarian failure (POF) and 29 with medically induced premature menopause (MIPM). RESULTS: The median (interquartile range) age of each group was: premenopausal = 29 (13) years, POF = 36 (8.0) years and MIPM = 38 (4.0) years (p < 0.001). The reported frequency of menopausal symptoms differed across the groups for difficulty sleeping (premenopausal = 26%, POF = 44%, MIPM = 69%, p = 0.01), some depression symptoms (premenopausal = 4.4-22%, POF = 20-25%, MIPM = 38-59%, p < 0.05), hot flushes (premenopausal = 4.4%, POF = 28%, MIPM = 59%, p < 0.001), sweating at night (premenopausal = 4.4%, POF = 20%, MIPM = 52%, p < 0.001) and loss of interest in sex (premenopausal = 17%, POF = 52%, MIPM = 54%, p = 0.02). More women with premature menopause than premenopausal women reported taking prescription medication (premenopausal = 52%, POF = 92%, MIPM = 86%, p = 0.002), perceived that hormone therapy (HT) was associated with increased breast cancer risk (premenopausal = 43%, POF = 56%, MIPM = 79%, p = 0.03) and that HT prevented fractures (premenopausal = 13%, POF = 56%, MIPM = 39%, p = 0.01). Most women reported not knowing risks/benefits of bioidentical hormone therapy (premenopausal = 86%, POF = 56%, MIPM = 75%, p = 0.06). Regarding health-related behavior around prevention and screening, varying rates of bone densitometry (premenopausal = 4.4%, POF = 64%, MIPM = 59%, p < 0.001), blood glucose testing (premenopausal = 39%, POF = 67%, MIPM = 57%, p = 0.16) and cholesterol testing (premenopausal = 22%, POF = 71%, MIPM = 54%, p = 0.003) were reported. CONCLUSIONS: Differences in understanding of menopausal therapies and health-related behavior exist among women with premature menopause of differing etiology and premenopausal women. While perceived understanding of HT was greater than other therapies, targeted education is needed regarding specific risks/benefits of menopausal therapies and regarding preventive health screening after premature menopause.M. Gibson-Helm, H. Teede and A. Vincen
Patterns in the provision of government-subsidised hormonal postpartum contraception in Queensland, Australia between 2012 and 2018: a population-based cohort study
No full textFirst published June 23, 2023Background: Short birth intervals and unintended pregnancy are associated with poorer maternal and infant outcomes. There is a risk of pregnancy during the immediate postpartum period unless contraception is initiated. This retrospective cohort study aimed to capture the current patterns of hormonal contraceptive provision within 12 months postpartum in a high-income country. Methods: We used a linked administrative dataset comprising all women who gave birth in Queensland, Australia between 1 July 2012 and 30 June 2018 (n=339 265 pregnancies). We described our cohort by whether they were provided with government-subsidised hormonal contraception within 12 months postpartum. The associations between hormonal postpartum contraceptive provision and demographic and clinical characteristics were examined using univariate and multivariate logistic regression and presented in terms of crude and adjusted odds ratios with 95% confidence intervals. Results: A majority of women (60.2%) were not provided with government-subsidised hormonal postpartum contraception within 12 months postpartum. Women who were younger (<25 years), were overweight or obese, smoked, were born in Australia, were non-Indigenous, gave birth in a public hospital, or were in the lowest socioeconomic status group were more likely to be provided with postpartum contraception after adjusting for other covariates, compared with their counterparts. Conclusions: Strategies to increase the provision and uptake of contraception in the immediate postpartum period are needed to prevent short birth intervals and unintended pregnancy and ensure women’s fertility intentions are enacted. Ongoing research is needed to examine the factors influencing women’s access to contraceptive services and, further, the types of contraception provided.Alayna Carrandi, Claudia Bull, Yanan Hu, Luke E Grzeskowiak, Helena Teede, Kirsten Black, Emily Callande
- …
